Printer Friendly

HBV revaccination recommended for HIV-infected teens.

FROM THE PEDIATRIC INFECTIOUS DISEASE JOURNAL

CONSIDER REVACCINATING all perinatally HIV-infected adolescents who did not initiate highly active antiretroviral therapy (HAART) at the time of initial infant hepatitis B virus (HBV) vaccination, with a three-dose HBV schedule, recommended researchers at Mahidol University, Bangkok, in a recent study.

In a prospective study from March 2012 to March 2014 ultimately involving 162 perinatally HIV-infected adolescents with immune reconstitution, only 3.6% were receiving HAART at the time of initial infant HBV vaccination and 96.3% had undetectable antihepatitis B surface antibodies (anti-HBs) at baseline. Adolescents with breakthrough HBV infection had been excluded from the cohort.

After the first dose of HBV revaccination, 58% of the adolescents developed anti-HBs greater than or equal to 10 mIU/mL; 27.8% had anti-HBs greater than or equal to 100 mIU / mL and thus didn't receive the third revaccination. Of the 117 who received the third dose, 97% developed anti-HBs greater than or equal to 10 mIU/mL. There were four nonresponders after the three doses who were given an additional three doses; they then had anti-HBs greater than or equal to 100 mIU/mL.

In a multivariate analysis, there was no independent factor that was associated with the presence of immune memory defined as anti-HBs greater than or equal to 100 mIU/mL, wrote lead researcher Keswadee Lapphra, MD, and her associates (Ped Inf Dis J. 2017. doi: 10.1097/ inf.0000000000001613).

In a previous study, 71% of three-dose revaccinated persons retained protective antibodies against HBV at 3-year follow-up; this was a similar rate to that reported in healthy HIV-infected children after their infant primary HBV series (Vaccine. 2011 May 23;29[23]:3977-81), they said.

cnellist@frontlinemedcom.com

COPYRIGHT 2017 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:ASTHMA
Author:Nellist, Catherine Cooper
Publication:Pediatric News
Article Type:Clinical report
Date:May 1, 2017
Words:284
Previous Article:Asthma inhaler linked to adrenocorticotropic suppression.
Next Article:Long-term peanut sublingual immunotherapy found safe.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters